Effekten av fottøysgenerert biomekanisk manipulasjon på symptomer på stressurininkontinens (SUI)
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
FGBMM (fottøysgenerert biomekanisk manipulasjon) påvirker nevromuskulære mønstre i bekkenmuskulaturen. Selv om det ikke har vært publiserte studier etter vår kunnskap som undersøker effekten av FGBMM på urininkontinens, har FGBMM vist seg å forårsake forstyrrelser i balanse og gange som skaper dynamikk som ligner på dynamiske lumbosakrale stabiliseringsøvelser. Til støtte for denne teorien, selv om den ikke er publisert, har en av grunnleggerne av teknikken, Avi Elbaz, notert anekdotiske bevis på at pasienter som hadde SUI (stress urininkontinens) og gjennomgikk FGBMM for kne- eller korsryggsmerter rapporterte bedring av inkontinens. Etterforskerne foreslår at FGBMM induserer de samme biomekaniske forbedringene som LPSE (lumbopelvic stabiliseringsøvelser) som har vist fordeler for inkontinens. Podene på fottøyet kan plasseres for å utfordre pasientens balanse på en måte som ligner på måten trampoliner brukes i LPSE. I stedet for å instruere pasienter om å trekke sammen den nedre stammen og bekkenbunnsmuskulaturen, slik det vanligvis gjøres for LPSE, kan skoene som brukes i FGBMM kalibreres på en måte som gjør at denne samkontraksjonen skjer uten at pasienten er klar over det. Fordelaktig plassering av bekken og ryggrad kan også oppnås ved strategisk plassering av belgene uten å måtte instruere pasienten om kompliserte manøvrer. En ekstra fordel med FGBMM er at denne øvelsen gjøres med økt intraabdominalt trykk som etterligner tilstanden og innstillingen når inkontinens oppstår i stedet for statisk trening som brukes i PFT. Mens de utfører vanlige aktiviteter, sitter folk naturlig på huk og gjør andre aktiviteter som øker det intraabdominale trykket. Videre er FGBMM mer praktisk for personer med travle timeplaner fordi det kan oppnås med en mye mindre tidsforpliktelse fra pasienten enn tradisjonell PFT siden det gjøres under normal aktivitet. Ved å utnytte den utmerkede etterlevelsen og de kliniske fordelene med FGBMM på relaterte forhold, foreslår etterforskerne å evaluere effekten av FGBMM i tillegg til bekkenbunnsterapi for å forbedre symptomene på stressurininkontinens i en urban befolkning i indre by.
En potensiell bruk av FGBMM ved bruk av sko som et tillegg til tradisjonell bekkenbunnsterapi kan gi en mer effektiv terapi med bedre vedheft. Problemer med tradisjonell terapi inkluderer dårlig pasienttilslutning (pasienter fullfører ofte ikke øktene og har dårlig etterlevelse (ca. 50%), manglende fortsettelse i et pågående program, som fører til tilbakefall og behov for ny behandling eller til og med liten klinisk nytte. I tillegg er tilgangen til bekkenbunnsbehandling begrenset for mange pasienter siden det ikke er nok tilgjengelige polikliniske terapitjenester til å møte behovene til alle pasienter. Å finne et ekstra treningsprogram som vil øke etterlevelsen og forbedre pasientresultatene med bedre kliniske fordeler er en høy prioritet både fra pasientbehandling og kostnadsstyringsperspektiv.
FGBMM-bruk av sko overvinner potensielt mange av disse problemene med å forbedre/modifisere unormal biomekanikk i bekkenbunnsmuskulaturen (derfor reduserer inkontinens), og et hjemmebasert treningsprogram som bruker fottøy som forårsaker trening med normal aktivitet ved å fremme forstyrrelser. Denne biomekaniske tilnærmingen kan betydelig forbedre symptomene på urininkontinens hos pasienter med Stress SUI eller Blandet urininkontinens. Ved å utnytte den rapporterte utmerkede etterlevelsen og kliniske fordelen med FGBMM hos pasienter med relaterte tilstander, foreslår etterforskerne å evaluere den biomekaniske treningen (bruke en passende kalibrert sko hjemme i en foreskrevet tid hver dag) som en konservativ behandling som kan supplere tradisjonell bekkenbunnsterapi, medisiner og til og med kirurgiske inngrep for det samme i en indre bybefolkning.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Atira H. Kaplan, MD
- Telefonnummer: 917-331-0611
- E-post: akaplan@montefiore.org
Studer Kontakt Backup
- Navn: Anna M. Lasak, MD
- Telefonnummer: 718-920-9171
- E-post: alasak@montefiore.org
Studiesteder
-
-
New York
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center - Medical Park Campuses
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Beskrivelse
Inklusjonskriterier:
- Stress eller blandet urininkontinens, basert på UDI-6.
- Kvinner mellom 18-75 år.
- Vekt mindre enn 350 lbs.
- Ambulerende og aktive pasienter som kan delta i et rehabiliteringsprogram som inkluderer daglig gange
- Kunne gå minst 50 meter og scoret positivt på STEADI-testen
- Kunne forstå, lese og signere skjemaet for informert samtykke
- Engelsk eller spansktalende
Ekskluderingskriterier:
- Tidligere operasjon for inkontinens
- Bekkenbunnsterapi i løpet av de siste 6 månedene.
- For tiden gravid
- Overveiende urge-inkontinens.
- Pasienter med mer enn 3 fall i løpet av de siste 52 ukene, ELLER ethvert balanserelatert fall med skade de siste 52 ukene.
- Pasienter som viser manglende fysisk eller mental evne til å utføre eller overholde studieprosedyren.
- Pasienter med en historie med patologisk osteoporotisk fraktur
- Eventuelle alvorlige kardiovaskulære komorbiditeter som forbyr påmelding til et aktivt treningsprogram
- Aktiv hjertesykdom (iskemi eller hjertesviktinnleggelse innen 24 uker) og aktiv KOLS (forverring innen 24 uker)
- Aktive maligniteter ved pågående behandling
- Pasient med nevrologisk gangmønster.
- Pasient som trenger hjelpemiddel under ganganalyse.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Aktiv komparator: Traditional Pelvic Floor Physical Therapy (PFPT)
Up to six sessions, with one session every alternate week.
|
Participant will receive six sessions of PFPT, up-to one sessions every alternate week.
This will involve exercise and modalities as decided by medical providers and therapists.
Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
|
|
Eksperimentell: FGBMM plus Traditional Pelvic Floor Physical Therapy (PFPT)
Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
|
Participants will have FGBMM using shoes with pertupods along with traditional PFPT over the course of six months.
This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months.
Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week.
This will involve exercise and modalities as decided by medical providers and therapists.
Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of Stress Urinary Incontinence (SUI) Symptoms
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
Severity of SUI symptoms was measured using the six-item Urogenital Distress Inventory (UDI-6).
The UDI-6 is a validated, patient-reported questionnaire which assesses the severity of symptoms of urinary incontinence.
It includes questions evaluating the frequency of urination, incontinence/leakage, difficulty with complete bladder emptying, and pain.
Responses on the UDI-6 are rated on a 5-point scale ranging from 0 ("No/Not present") to 4 ("Quite a bit").
Raw scores were summed, averaged, and multiplied by 25 to yield a final score scale ranging from 0-100.
Higher scores are indicative of greater distress due to symptom severity.
Results are summarized by study arm.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of Life as Determined by the Urinary Impact Questionnaire (UIQ-7)
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
Quality of Life will be determined with the use of the UIQ-7 subscale component of the Pelvic Floor Impact Questionnaire-short form 7 (PFIQ-7) questionnaire.
Specifically, the UIQ-7 questions within the PFIQ-7 are used to assess the impact of bladder or urine symptoms or conditions on a participant's daily function and activities, social health, or mental health over the prior 3 months.
Participants provide responses for each question on 4-point scale ranging from 0 ("Not at all") to 3 ("Quite a bit").
Mean scores are averaged and multiplied by 100/3 to yield an overall possible score of 0-100, such that higher scores are indicative of a greater negative impact on quality of life from pelvic floor dysfunction.
Scores are summarized by study arm using basic descriptive statistics.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Pelvic Floor Muscle (PFM) Activity - Average Contraction
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
PFM Activity was assessed during each visit by surface electromyography (sEMG).
sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe.
Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles.
Electrical signals (microvolts) were measured during specific tasks and PFM average contraction, maximum contraction, and average rest results were calculated and reported in microvolts.
Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence.
Average contraction results values are summarized by study arm using basic descriptive statistics.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Pelvic Floor Muscle (PFM) Activity - Maximum Contraction
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
PFM Activity was assessed during each visit by surface electromyography (sEMG).
sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe.
Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles.
Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts.
Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence.
Maximum contraction results values are summarized by study arm using basic descriptive statistics.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Pelvic Floor Muscle (PFM) Activity - Average Rest
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
PFM Activity was assessed during each visit by surface electromyography (sEMG).
sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe.
Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles.
Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts.
Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence.
Average rest results values are summarized by study arm using basic descriptive statistics.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Pelvic Floor Muscle (PFM) Activity - Change From Average Contraction to Average Rest
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
PFM Activity was assessed during each visit by surface electromyography (sEMG).
sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe.
Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles.
Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts.
Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence.
Change From Average Contraction to Average Rest results values are summarized by study arm using basic descriptive statistics.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Pelvic Floor Muscle (PFM) Activity - Average Abdominal Contraction
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
PFM Activity was assessed during each visit by surface electromyography (sEMG).
sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe.
Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles.
Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts.
Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence.
Average Abdominal Contraction results values are summarized by study arm using basic descriptive statistics.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Adherence to Treatment
Tidsramme: Baseline to 24 weeks (~Six months)
|
Adherence to FGBMM and PFPT was assessed based on self-reporting of in-person PFPT visits and in-person calibration visits (Dual Therapy study arm only) on an end of study questionnaire.
Median number of visits is calculated and summarized by study arm.
|
Baseline to 24 weeks (~Six months)
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Total Healthcare Costs
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
Total costs associated with PFPT or PFPT+FGBMM will be summarized.
Costs will include those associated with physical therapy, emergency department (ED) visits, medications, imaging studies, surgical procedures, physician visits related to symptoms of incontinence, and total physician visits.
Mean costs will be summarized by study arm.
|
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
|
|
Gait Assessment
Tidsramme: Six months
|
The gait assessment consists of the Spatio-temporal gait assessment including the following parameters: gait velocity, cadence, step length, gait cycle phases, step width, toe-in/out angle, center of pressure trajectory single limb support and limb symmetry measured by gait analysis.
Results will be summarized by study arm.
|
Six months
|
|
Change in Total Healthcare Utilization
Tidsramme: 6 months
|
Change in total healthcare facility utilization, including physical therapy, ED visits, pharmacological treatments, imaging studies, surgical procedures, physician visits related to symptoms of incontinence and total physician visits, as assessed by patient interview.
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Hovedetterforsker: Anna M Lasak, MD, Montefiore Medical Center
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646-56. Epub 2003 Nov 14.
- Tsao H, Hodges PW. Immediate changes in feedforward postural adjustments following voluntary motor training. Exp Brain Res. 2007 Aug;181(4):537-46. doi: 10.1007/s00221-007-0950-z. Epub 2007 May 3.
- Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7). Am J Obstet Gynecol. 2005 Jul;193(1):103-13. doi: 10.1016/j.ajog.2004.12.025.
- Sapsford R. Rehabilitation of pelvic floor muscles utilizing trunk stabilization. Man Ther. 2004 Feb;9(1):3-12. doi: 10.1016/s1356-689x(03)00131-0.
- Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn. 1995;14(2):131-9. doi: 10.1002/nau.1930140206.
- Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010 Jan;21(1):5-26. doi: 10.1007/s00192-009-0976-9. Epub 2009 Nov 25.
- Ng K, Cheung RYK, Lee LL, Chung TKH, Chan SSC. An observational follow-up study on pelvic floor disorders to 3-5 years after delivery. Int Urogynecol J. 2017 Sep;28(9):1393-1399. doi: 10.1007/s00192-017-3281-z. Epub 2017 Feb 14.
- de Souza Abreu N, de Castro Villas Boas B, Netto JMB, Figueiredo AA. Dynamic lumbopelvic stabilization for treatment of stress urinary incontinence in women: Controlled and randomized clinical trial. Neurourol Urodyn. 2017 Nov;36(8):2160-2168. doi: 10.1002/nau.23261. Epub 2017 Mar 27.
- Barzilay Y, Segal G, Lotan R, Regev G, Beer Y, Lonner BS, Mor A, Elbaz A. Patients with chronic non-specific low back pain who reported reduction in pain and improvement in function also demonstrated an improvement in gait pattern. Eur Spine J. 2016 Sep;25(9):2761-6. doi: 10.1007/s00586-015-4004-0. Epub 2015 May 16.
- Ghaderi F, Mohammadi K, Amir Sasan R, Niko Kheslat S, Oskouei AE. Effects of Stabilization Exercises Focusing on Pelvic Floor Muscles on Low Back Pain and Urinary Incontinence in Women. Urology. 2016 Jul;93:50-4. doi: 10.1016/j.urology.2016.03.034. Epub 2016 Apr 5.
- Silva VR, Riccetto CL, Martinho NM, Marques J, Carvalho LC, Botelho S. Training through gametherapy promotes coactivation of the pelvic floor and abdominal muscles in young women, nulliparous and continents. Int Braz J Urol. 2016 Jul-Aug;42(4):779-86. doi: 10.1590/S1677-5538.IBJU.2014.0580.
- Solomonow-Avnon D, Levin D, Elboim-Gabyzon M, Rozen N, Peled E, Wolf A. Neuromuscular response of hip-spanning and low back muscles to medio-lateral foot center of pressure manipulation during gait. J Electromyogr Kinesiol. 2016 Jun;28:53-60. doi: 10.1016/j.jelekin.2016.02.010. Epub 2016 Mar 9.
- Tahtinen RM, Cartwright R, Tsui JF, Aaltonen RL, Aoki Y, Cardenas JL, El Dib R, Joronen KM, Al Juaid S, Kalantan S, Kochana M, Kopec M, Lopes LC, Mirza E, Oksjoki SM, Pesonen JS, Valpas A, Wang L, Zhang Y, Heels-Ansdell D, Guyatt GH, Tikkinen KAO. Long-term Impact of Mode of Delivery on Stress Urinary Incontinence and Urgency Urinary Incontinence: A Systematic Review and Meta-analysis. Eur Urol. 2016 Jul;70(1):148-158. doi: 10.1016/j.eururo.2016.01.037. Epub 2016 Feb 10.
- Utomo E, Korfage IJ, Wildhagen MF, Steensma AB, Bangma CH, Blok BF. Validation of the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) in a Dutch population. Neurourol Urodyn. 2015 Jan;34(1):24-31. doi: 10.1002/nau.22496. Epub 2013 Oct 26.
- Bush HM, Pagorek S, Kuperstein J, Guo J, Ballert KN, Crofford LJ. The Association of Chronic Back Pain and Stress Urinary Incontinence: A Cross-Sectional Study. J Womens Health Phys Therap. 2013 Jan;37(1):11-18. doi: 10.1097/JWH.0b013e31828c1ab3.
- Timmermans L, Falez F, Melot C, Wespes E. Validation of use of the International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF) for impairment rating: a transversal retrospective study of 120 patients. Neurourol Urodyn. 2013 Sep;32(7):974-9. doi: 10.1002/nau.22363. Epub 2012 Dec 31.
- Hides J, Stanton W, Mendis MD, Sexton M. The relationship of transversus abdominis and lumbar multifidus clinical muscle tests in patients with chronic low back pain. Man Ther. 2011 Dec;16(6):573-7. doi: 10.1016/j.math.2011.05.007. Epub 2011 Jun 8.
- Eliasson K, Elfving B, Nordgren B, Mattsson E. Urinary incontinence in women with low back pain. Man Ther. 2008 Jun;13(3):206-12. doi: 10.1016/j.math.2006.12.006. Epub 2007 Mar 23.
- Hajebrahimi S, Corcos J, Lemieux MC. International consultation on incontinence questionnaire short form: comparison of physician versus patient completion and immediate and delayed self-administration. Urology. 2004 Jun;63(6):1076-8. doi: 10.1016/j.urology.2004.01.005.
- Fultz NH, Burgio K, Diokno AC, Kinchen KS, Obenchain R, Bump RC. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol. 2003 Nov;189(5):1275-82. doi: 10.1067/s0002-9378(03)00598-2.
- van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. Measuring health-related quality of life in women with urogenital dysfunction: the urogenital distress inventory and incontinence impact questionnaire revisited. Neurourol Urodyn. 2003;22(2):97-104. doi: 10.1002/nau.10038.
- Persson J, Wolner-Hanssen P, Rydhstroem H. Obstetric risk factors for stress urinary incontinence: a population-based study. Obstet Gynecol. 2000 Sep;96(3):440-5. doi: 10.1016/s0029-7844(00)00950-9.
- Brown JS, Grady D, Ouslander JG, Herzog AR, Varner RE, Posner SF. Prevalence of urinary incontinence and associated risk factors in postmenopausal women. Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol. 1999 Jul;94(1):66-70. doi: 10.1016/s0029-7844(99)00263-x.
- Lemack GE, Zimmern PE. Predictability of urodynamic findings based on the Urogenital Distress Inventory-6 questionnaire. Urology. 1999 Sep;54(3):461-6. doi: 10.1016/s0090-4295(99)00246-0.
- Eisenstein SM, Engelbrecht DJ, el Masry WS. Low back pain and urinary incontinence. A hypothetical relationship. Spine (Phila Pa 1976). 1994 May 15;19(10):1148-52. doi: 10.1097/00007632-199405001-00010.
- Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res. 1994 Oct;3(5):291-306. doi: 10.1007/BF00451721.
- Minaire P, Jacquetin B. [The prevalence of female urinary incontinence in general practice]. J Gynecol Obstet Biol Reprod (Paris). 1992;21(7):731-8. French.
- Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency, and urgency in women. BMJ. 1988 Nov 5;297(6657):1187-9. doi: 10.1136/bmj.297.6657.1187. No abstract available.
- Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc. 1998 Apr;46(4):473-80. doi: 10.1111/j.1532-5415.1998.tb02469.x.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Mannlige urogenitale sykdommer
- Urologiske sykdommer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Graviditetskomplikasjoner
- Vannlatingsforstyrrelser
- Nedre urinveissymptomer
- Urologiske manifestasjoner
- Urininkontinens
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Urininkontinens, stress
- Bekkenbunnslidelser
Andre studie-ID-numre
Andre studie-ID-numre
- 2016-7163
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .